Edition:
United States

Roche Holding AG (RHHBY.PK)

RHHBY.PK on OTC Markets Group

32.02USD
22 Sep 2017
Change (% chg)

$-0.02 (-0.06%)
Prev Close
$32.04
Open
$32.07
Day's High
$32.12
Day's Low
$32.00
Volume
1,152,356
Avg. Vol
1,473,725
52-wk High
$36.82
52-wk Low
$25.25

Chart for

About

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas:... (more)

Overall

Beta: 0.61
Market Cap(Mil.): $220,462.70
Shares Outstanding(Mil.): 6,900.50
Dividend: 1.03
Yield (%): 3.21

Financials

  Industry Sector
P/E (TTM): -- 31.66 16.34
EPS (TTM): -- -- --
ROI: -- 15.09 14.66
ROE: -- 16.32 14.00

UPDATE 1-Roche wins expanded EU approvals for Gazyvaro, Actemra

* Medicines are part of Roche's biosimilars defence strategy (Adds details, company comment throughout)

Sep 22 2017

BRIEF-Recipharm starts cooperation with Roche

* RECIPHARM SIGNS LONG-TERM MANUFACTURING AGREEMENT WITH MAJOR NEW CUSTOMER AND ACQUIRES FACILITY IN SPAIN

Sep 20 2017

Swiss stocks - Factors to watch on Sept. 19

ZURICH, Sept 19The Swiss blue-chip SMI was seen opening 0.1 percent firmer at 9,057 points on Tuesday, according to premarket indications by bank Julius Baer .

Sep 19 2017

BRIEF-AbbVie announces positive topline results from phase 3 trial evaluating Venclexta/Venclyxto tablets in combination with Rituxan

* AbbVie announces positive topline results from phase 3 trial evaluating Venclexta™/Venclyxto™ (Venetoclax) tablets in combination with Rituxan® (Rituximab) for the treatment of patients with relapsed/refractory chronic lymphocytic Leukemia

Sep 18 2017

Biosimilar cancer drug threat closing in for Roche

LONDON The long-heralded threat of cut-price competition to its top-selling biological cancer medicines is finally becoming a reality for Roche, the world's biggest maker of oncology treatments.

Sep 18 2017

Biosimilar cancer drug threat closing in for Roche

LONDON, Sept 18 The long-heralded threat of cut-price competition to its top-selling biological cancer medicines is finally becoming a reality for Roche, the world's biggest maker of oncology treatments.

Sep 18 2017

Gates Foundation invests $40 mln in UK immunotherapy company

LONDON, Sept 18 The Bill & Melinda Gates Foundation is to invest up to $40 million in privately held British biotech company Immunocore to support its development of immunotherapies for infectious diseases.

Sep 18 2017

U.S. FDA approves biosimilar version of cancer drug Avastin

The U.S. Food and Drug Administration said on Thursday it has approved Amgen Inc's biosimilar version of Roche Holding AG's cancer drug Avastin.

Sep 14 2017

RPT-U.S. FDA approves biosimilar version of cancer drug Avastin

Sept 14 The U.S. Food and Drug Administration said on Thursday it has approved Amgen Inc's biosimilar version of Roche Holding AG's cancer drug Avastin.

Sep 14 2017

BRIEF-U.S. FDA approved Amgen's Mvasi as a biosimilar to Avastin

* U.S. FDA says approved Amgen's Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer

Sep 14 2017

Competitors

Earnings vs. Estimates